Atomoxetine + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Feb 1, 2005 → Sep 1, 2006
NCT ID
NCT00191295About Atomoxetine + Placebo
Atomoxetine + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191295. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00962104 | Phase 3 | Completed |
| NCT00716274 | Approved | Completed |
| NCT00607919 | Approved | Completed |
| NCT00546910 | Approved | Completed |
| NCT00617201 | Phase 2 | Completed |
| NCT00406354 | Approved | Completed |
| NCT00380692 | Approved | Completed |
| NCT00260533 | Phase 2/3 | Completed |
| NCT00191542 | Phase 3 | Completed |
| NCT00191295 | Phase 2/3 | Completed |
| NCT00190957 | Approved | Completed |
| NCT00386581 | Phase 3 | Completed |
| NCT00611533 | Pre-clinical | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Phase 3 | 77 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine hydrochloride + Placebo | Eli Lilly | Approved | 85 |
| CLONICEL (Clonidine HCl sustained release) | Shionogi | Phase 3 | 77 |
| Donepezil hydrochloride + Placebo | Eisai | Phase 3 | 77 |
| LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule) | Eli Lilly | Phase 2/3 | 65 |
| Atomoxetine + Placebo | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Pre-clinical | 23 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride + Placebo | Eli Lilly | Approved | 85 |
| atomoxetine | Eli Lilly | Phase 3 | 77 |
| atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo | Eli Lilly | Phase 3 | 77 |